Latest healthcare news

A paper from America published by the CDC shows that people who have received a vaccine booster are reporting side effects which are similar to those after the second dose.  The report relies on more than 12,500 submissions via V-safe, the CDC smartphone based...

An interesting paper published on 9th September 2021, in Nature Human Behaviour by Yang and others looked at the effect of remote working on collaboration amongst information workers.   The COVID-19 pandemic caused a rapid shift to full time remote work for...

An interesting comment by Sandmann published on September 22nd 2021 in Lancet Infectious Diseases considers the vaccination rollout in Israel. In The Lancet Infectious Diseases, Eric Haas and colleagues estimated the benefits of the rapid mass roll-out of the Pfizer...

A comment article published by Monti and others in The Lancet September 19th argues that to build a post-pandemic future, in which everyone's health is protected and promoted, we must learn from the events of the COVID-19 pandemic and previous crises. The Pan-European...

An interesting article in Science Advances published by Larremore and others in January 2021 looks at this important subject. Because SARS-CoV-2 can spread from individuals with presymptomatic, symptomatic, and asymptomatic infections, the reopening of societies and...

A helpful research study published by Hippisley-Cox and others in the BMJ 17th September 2021 helps to analyse this. They identified a range of important clinical risk factors for severe COVID-19 outcomes in people in the UK, 14 days or more after COVID-19 vaccination...

Throughout the COVID-19 Pandemic countries relied on a variety of ad hoc order control protocols to allow for non-essential travel while safeguarding public health. These included quarantining all travellers to restricting entry from select nations based on population...

Florian Kramer and others cite in the New England Journal of Medicine that the efficacy of two injections of the mRNA vaccines such as Moderna and Pfizer is high in preventing symptomatic SARS-CoV-2 infection in persons without previous coronavirus...

A preprint published in medRxiv August 15th 2021, by Gilbert and others reviewed this issue.  In the Coronavirus efficacy trial, they found the mRNA-1273 vaccine, the Moderna vaccine was 94% efficacious against COVID-19 disease.  SARS-CoV-2 antibody...

Safety of the messenger RNA Pfizer vaccine was evaluated by Barda and others and published in the New England Journal of Medicine on August 25th.  Background trials showed that messenger RNA based vaccines against severe acute respiratory syndrome coronavirus,...

Professor Stebbing in his daily update expands on this.  He suggests that there are falls in cases across two out of the five European countries but also a continued increase in the number of sick patients in hospital in the United Kingdom, Italy and...

An interesting paper published in the New England Journal of Medicine describes this as a vaccine which could prevent infection caused by known and future variants of concern as well as infection with pre-emergent sarbecoviruses i.e. those with potential to cause...